Pharmaceutical Intermediates
- • Analgesics (57)
- • Anesthetics (52)
- • Anti-Addiction Agents (8)
- • Antibacterials (117)
- • Anticonvulsants (20)
- • Antidementia Agents (23)
- • Antidepressants (35)
- • Antiemetics (24)
- • Antifungals (24)
- • Antigout Agents (9)
- • Anti-inflammatory Agents (28)
- • Antimigraine Agents (21)
- • Antineoplastics (427)
- • Antiparasitics (11)
- • Antiparkinson Agents (28)
- • Antipsychotics (54)
- • Antispasticity Agents (12)
- • Antivirals (146)
- • Anxiolytics (16)
- • Blood Glucose Regulators (105)
- • Blood Products (61)
- • Cardiovascular Agents (179)
- • CNS Agents (22)
- • Dental and Oral Agents (8)
- • Dermatological Agents (19)
- • Electrolytes (15)
- • Gastrointestinal Agents (62)
- • Genetic/Enzyme Disorder (12)
- • Genitourinary Agents (47)
- • Immunological Agents (36)
- • Metabolic Bone Disease (6)
- • Ophthalmic Agents (307)
- • Respiratory Tract (51)
- • Skeletal Muscle Relaxants (5)
- • Sleep Disorder Agents (28)
- • Oled Material Intermediate (333)
- • Heterocyclic Compound (9764)
- • Bulk Drug Intermediates (17724)
Related News
-
India Imposes Final Anti‑Dumping Duties on Ethylenediamine from China, EU, Saudi Arabia, and Taiwan, China, with Top Rate of $575/tonne
2026-06-30 -
US Chemical Shutdown Wave Expands, PS Units Become the Hardest Hit Segment
2026-06-30 -
EU mulls expanding tariff scope on Chinese chemicals, sector-wide measures in the pipeline
2026-06-23 -
BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync
2026-06-26 -
Another Major Coating Manufacturer Acquired by a Central SOE: BNBM Acquires SUNROAD Group for Over RMB 300 Million, Locks in Three-Year Performance Pledge
2026-06-29 -
Covestro Builds New 660,000-ton MDI Plant in China: Global Supply Gap Meets Chinese Overcapacity Head-On
2026-07-01
Anticonvulsants
TERT-BUTYL N-(4-HYDROXYBUTYL)CARBAMATE
(75178-87-9)-
- / 99.00%
-
-
Industrial Grade / 99%
-
Request for quotation , get quotes from more suppliers.
-
pharmaceutical grade / 99%
$1/KG EXW
-
Industrial Grade / 99.00%
-
-
Request for quotation , get quotes from more suppliers.
More Information
Anticonvulsants, also known as anti-seizure or anti-epileptic agents, are substances used to prevent or reduce the frequency and severity of seizures. They are widely applied in the treatment of epilepsy, neuropathic pain, and certain psychiatric disorders, making them essential in modern neurology and pharmaceutical development.
Key mechanisms of action for anticonvulsants include:
• Stabilizing neuronal membranes by blocking sodium or calcium ion channels, reducing abnormal electrical activity in the brain.
• Enhancing the activity of inhibitory neurotransmitters such as GABA, helping to suppress seizure activity.
• Reducing excitatory neurotransmitter release, thereby lowering the risk of overactive neuronal firing.
Factors to consider when selecting anticonvulsant raw materials:
• Spectrum of activity – some agents are effective for generalized seizures, while others target focal or partial seizures.
• Safety and tolerability – side effect profile, drug interactions, and patient compliance are critical.
• Formulation requirements – solubility, stability, and compatibility with excipients in tablets, capsules, or injectable solutions.
• Regulatory compliance – adherence to pharmaceutical safety and manufacturing standards.
Common anticonvulsant raw materials include carbamazepine, valproic acid, lamotrigine, and gabapentin. They are typically supplied in crystalline or powder forms for use in oral solid dosage forms, solutions, or controlled-release formulations. These agents are not only vital in epilepsy management but also increasingly used in treating neuropathic pain and bipolar disorder.
Frequently Asked Questions
Anticonvulsants, also known as antiepileptic drugs (AEDs), are medications used to prevent or reduce the frequency and severity of seizures in conditions like epilepsy. They work by stabilizing electrical activity in the brain, often through mechanisms such as enhancing GABA inhibition, blocking sodium or calcium channels, or modulating glutamate activity. Understanding their mechanism helps clinicians choose the most appropriate therapy for specific seizure types.
Common anticonvulsant medications include older-generation drugs like phenytoin, valproic acid, and carbamazepine, as well as newer agents such as levetiracetam, lamotrigine, and topiramate. Each class has distinct pharmacokinetics, side effect profiles, and indications—ranging from focal and generalized seizures to mood stabilization or neuropathic pain management. Choosing the right type depends on the patient’s diagnosis, age, comorbidities, and potential drug interactions.
Anticonvulsants can cause a range of side effects, including drowsiness, dizziness, nausea, weight changes, and cognitive impairment. Some may lead to serious reactions like Stevens-Johnson syndrome (e.g., with lamotrigine or carbamazepine) or hepatotoxicity (e.g., with valproic acid). Regular monitoring of blood levels, liver function, and skin reactions is essential, especially during treatment initiation or dose adjustments.
Beyond epilepsy, anticonvulsants are commonly prescribed for off-label uses such as bipolar disorder (e.g., valproate, lamotrigine), neuropathic pain (e.g., gabapentin, pregabalin), and migraine prophylaxis (e.g., topiramate). Their ability to modulate neuronal excitability makes them effective in various neurological and psychiatric conditions. However, use should always be guided by clinical evidence and professional medical advice.
Selecting an appropriate anticonvulsant involves evaluating several key factors: the type of seizure or condition being treated, the patient’s age and gender (e.g., teratogenic risks in women of childbearing age), comorbid medical conditions, potential drug interactions, side effect profile, dosing convenience, and cost. Therapeutic drug monitoring may also be necessary for certain anticonvulsants to ensure efficacy and safety.